Sartorius AG represents a set of values and corporate philosophy focused on innovation, quality, and sustainability. As a leading international laboratory and pharmaceutical equipment provider, Sartorius AG ensures customer satisfaction by continually developing cutting-edge technologies and maintaining the highest standards of product excellence. With a strong commitment to sustainability, the company aims to create long-term value for its stakeholders, including customers, employees, and investors. Sartorius AG's dedication to ethical practices, collaboration, and social responsibility underpins its mission to contribute to the progress of science and the betterment of society.

Sartorius AG, a leading biotechnology and laboratory equipment provider, is primarily present in various countries and regions worldwide. The company's global footprint extends across major markets, including North America, Europe, Asia-Pacific, and Latin America. With its headquarters in Goettingen, Germany, Sartorius AG maintains a strong presence in its home country, serving as a hub for research and production. Moreover, the company has established subsidiaries and offices in key countries such as the United States, China, Japan, France, and many others, enabling Sartorius AG to cater to a diverse customer base and foster strategic collaborations on a global scale.

Sartorius AG, a renowned company in the stock market, has accomplished several significant milestones. With a strong focus on precision and excellence, Sartorius AG has achieved remarkable growth and recognition over the years. Some noteworthy achievements include expanding its global presence by establishing subsidiaries and offices in key markets, continuously innovating and launching breakthrough products, and solidifying strategic partnerships with leading industry players. Sartorius AG has also received prestigious awards for its cutting-edge technology and outstanding performance in the life sciences and biopharmaceutical sectors. Through its dedication to quality and customer satisfaction, Sartorius AG has established itself as a trusted and forward-thinking company in the stock market.

Sartorius AG is a renowned German company with a rich history and background. Founded in 1870, Sartorius specializes in manufacturing and distributing laboratory and process technologies. With a strong focus on biopharmaceutical research and production, the company is widely recognized for its innovative solutions in filtration, weighing, and separation technologies. Sartorius AG has expanded globally and established a strong presence in over 110 countries, catering to a diverse range of industries such as food, healthcare, and biotechnology. With a legacy of excellence, Sartorius AG continues to be a leading provider of cutting-edge scientific instruments and services.

The main competitors of Sartorius AG in the market include Thermo Fisher Scientific, Danaher Corporation, and Merck KGaA.

Sartorius AG is primarily active in the life sciences industry.

The business model of Sartorius AG, a renowned company in the stock market, revolves around providing innovative and high-quality products and solutions for biopharmaceutical research and manufacturing. Sartorius AG specializes in the fields of laboratory instruments, consumables, and services, catering to the needs of pharmaceutical and biotech companies worldwide. With a strong focus on bioprocessing technologies, Sartorius AG enables its customers to efficiently develop and produce medications. Through continuous advancements in technology and a customer-oriented approach, Sartorius AG has established itself as a leading supplier in the life science industry, contributing significantly to the advancement of healthcare.

De K/W-verhouding kan momenteel niet worden berekend voor Sartorius.

De KUV kan momenteel niet worden berekend voor Sartorius.

De AlleAktien Kwaliteitsscore voor Sartorius is 4/10.

De omzet kan momenteel niet worden berekend voor Sartorius.

De winst kan momenteel niet berekend worden voor Sartorius.

Sartorius AG is a global provider of innovative technologies and solutions for biopharmaceuticals, as well as for laboratory, food, and environmental applications. The company has two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions supplies the necessary technologies and products for the production of biopharmaceuticals, including filtration systems, disposable bioreactors, peristaltic pumps, and process control systems. Lab Products & Services offers innovative laboratory instrumentation and consumables for research, development, quality assurance, and control. The company is known for its use of disposable systems in biopharmaceuticals, which ensure process sterility and reduce cleaning and validation efforts. The company is focused on innovation and customer orientation to remain competitive in a rapidly changing global market. It invests in research and development to offer the most future-proof and efficient technologies and solutions to its customers. Overall, Sartorius operates in a growing industry driven by an increase in global patient data, the rising demand for personalized medicine, and the need for more efficient production processes.

Sartorius keert een dividend van 0 EUR uit, verdeeld over 1 betalingen per jaar.

Sartorius keert 1 keer per jaar een dividend uit.

De ISIN van Sartorius is DE0007165607.

Het WKN van Sartorius is 716560.

De ticker van Sartorius is SRT.DE.

Binnen de laatste 12 maanden betaalde Sartorius een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Sartorius naar verwachting een dividend van 1,85 EUR betalen.

De dividendrendement van Sartorius is momenteel .

Sartorius betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden april, april, april, mei.

Sartorius betaalde de afgelopen 26 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 1,85 EUR verwacht. Dit komt overeen met een dividendrendement van 1,04 %.

Sartorius wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Sartorius van 4-4-2024 ter hoogte van 0,73 EUR te ontvangen, moest je het aandeel voor de ex-datum op 2-4-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 4-4-2024.

In het jaar 2023 heeft Sartorius 1,25 EUR aan dividenden uitgekeerd.

De dividenden van Sartorius worden in EUR uitgekeerd.